Search | Clinical Trials Finder

Conditions: Diabetic Foot Ulcer (DFU)
Interventions: FoundationDRS Solo, Standard of Care; Other
Lead sponsor: Samaritan Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Diabetic Foot Ulcer
Interventions: SOC and Advanced Bioengineered Skin Substitute, SOC and Active Comparator; Device · Other
Lead sponsor: Encoll Corp; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Los Angeles, California • South Miami, Florida • Salem, Virginia

Conditions: Diabetic Foot Ulcer
Interventions: Standard of Care, Nitric Oxide Therapy 2x week 6 min. plus standard of care, Nitric Oxide Therapy 2x week 12 min. plus standard of care, Nitric Oxide Therapy 4x week 6 min. plus standard of care, Nitric Oxide Therapy 4x week 12 min. plus standard of care; Device
Lead sponsor: Origin Inc.; Industry
Eligibility: 22 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 15
States / cities: Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 11 more

Conditions: Wound
Interventions: Standard of Care Treatment or Standard of Care Treatment plus Miro3D Wound Matrix; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetic Foot Ulcer, Venous Leg Ulcer, Ulcer Foot, Leg Ulcer
Interventions: Standard of Care-DFU, AmnioCore - DFU, Amnio Quad-Core - DFU, Standard of Care-VLU, Amnio Tri-Core - VLU, Amniocore Pro +; Other
Lead sponsor: Stability Biologics; Industry
Eligibility: 21 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Circleville, Ohio

Conditions: Diabetic Foot, DFU, Diabetic Foot Ulcer, Foot Ulcer, Diabetic, Ulcer Foot, Venous Leg Ulcer, Leg Ulcer, Leg Ulcers Venous, Ulcer
Interventions: Standard of Care DFU, Tri-Membrane Wrap™ DFU, Membrane Wrap™ DFU, Membrane Wrap-Lite™ DFU, Membrane Wrap-Hydro™ DFU, Standard of Care VLU, Tri-Membrane Wrap™ VLU, Membrane Wrap™ VLU, Membrane Wrap-Lite™ VLU, Membrane Wrap-Hydro™ VLU; Other
Lead sponsor: BioLab Holdings; Industry
Eligibility: 18 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philidelphia, Pennsylvania

Conditions: Pressure Ulcer, Ulcer, Ulcer, Pressure, Pressure Injury
Interventions: ACApatch™, caregraFT™, Standard of Care; Other
Lead sponsor: Tiger Biosciences, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Monroeville, Pennsylvania

Conditions: Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer, Diabetic, Foot Ulcer
Interventions: Standard of Care, EPIEFFECT, EPIXPRESS; Other
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Monroeville, Pennsylvania

Conditions: Venous Insufficiency, Venous Reflux, Lower Extremity Ulcer
Interventions: MIST Therapy; Device
Lead sponsor: Celleration, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Weymouth, Massachusetts

Conditions: Diabetic Foot Ulcer, Venous Leg Ulcer
Interventions: Amnion-Intermediate-Chorion, Amnion-Chorion-Amnion, Standard of Care; Other · Procedure
Lead sponsor: Cellution Biologics; Industry
Eligibility: 18 Years to 98 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Jacksonville, Florida • Cincinnati, Ohio • Weslaco, Texas + 1 more

Conditions: Head and Neck Cancer, Oral Mucositis
Interventions: Standard of Care Oral Hygiene, Oral mucosal deterging and dental prophylaxis; Other · Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU)
Interventions: DermaBind TL; Biological
Lead sponsor: HealthTech Wound Care; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: DeLand, Florida • Palm Beach Gardens, Florida • Sweetwater, Florida + 7 more

Conditions: Thermal Burns
Interventions: NexoBrid, Standard of Care; Drug · Procedure
Lead sponsor: MediWound Ltd; Industry
Eligibility: 0 Years to 17 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 13
States / cities: Phoenix, Arizona • Gainesville, Florida • Miami, Florida + 10 more

Conditions: Venous Leg Ulcer
Interventions: NeoThelium FT (HCT/P 361); Other
Lead sponsor: NuScience Medical Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Metairie, Louisiana • Slidell, Louisiana

Conditions: Diabetic Foot Ulcer
Interventions: MIST Therapy, SOC - Standard of Care; Device · Other
Lead sponsor: Celleration, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Diabetic Foot Ulcer
Interventions: Orion TM Amniotic Membrane Allograft, Standard of Care (SOC); Device · Procedure
Lead sponsor: Legacy Medical Consultants; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Palm Springs, California • San Francisco, California • Vista, California + 5 more

Conditions: Diabetic Foot Ulcers (DFUs), Venous Leg Ulcers (VLUs), Pressure Ulcers, Surgical Wound Dehiscence (SWD), Chronic Wounds, Undermined and Tunneling Wounds
Interventions: Acellular Porcine-Derived Wound Matrix; Device
Lead sponsor: Reprise Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Coconut Creek, Florida • Tamarac, Florida

Conditions: Open Wound
Interventions: NeoThelium FT; Other
Lead sponsor: NuScience Medical Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Hammond, Louisiana

Conditions: Diabetic Foot Ulcers (DFUs)
Interventions: Bonvadis® (NWBOT), Clostridial Collagenase Ointment; Device
Lead sponsor: Oneness Biotech Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: North Port, Florida • Palm Coast, Florida • South Miami, Florida + 7 more

Conditions: Diabetic Foot Ulcer
Interventions: Standard of Care, PuraPly AM, PuraPly XT; Other · Device
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Clevland, Ohio

Conditions: Diabetic Foot Ulcer
Interventions: Amnio Excel + weekly, Amnio Excel + max every 2 weeks; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetic Foot Ulcer
Interventions: NOX1416 and SOC, SOC (Standard of care); Drug · Procedure
Lead sponsor: NOxy Health Products, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Phoenix, Arizona • Tucson, Arizona • Coral Gables, Florida + 9 more

Conditions: Diabetic Foot Ulcer
Interventions: Tenex TXB MicroTip Ultrasound system plus SOC, Standard of Care for diabetic foot ulcer; Device · Other
Lead sponsor: Tenex Health Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Mobile, Alabama • St. George, Utah

Conditions: Venous Leg Ulcer (VLU)
Interventions: Amnion-Intermediate-Chorion, Standard of Care (SOC); Other · Procedure
Lead sponsor: Cellution Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rocky Mount, North Carolina

Search by objective public record fields.

Evaluating the Efficacy of FoundationDRS Solo in Addition to Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers

Clinical Study to Compare Two Skin Substitute Categories for Their Effectiveness to Treat Diabetic Foot Ulcers

A Feasibility Study of Advance Plasma Therapy001 Plasma/Nitric Oxide Therapy for the Treatment of Diabetic Foot Ulcers

Miro3D Randomized Controlled Trial (RCT)

Modified Multi-Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of DFU and VLUs

Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers

Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers

Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs

Effects of Non Contact Low Frequency Ultrasound in Healing Venous Leg Ulcers

Study Evaluating Several CAMPs in Nonhealing Diabetic Foot and Venous Leg Ulcers

Commensal Oral Microbiota in Head and Neck Cancer

A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL

A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care

Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Venous Leg Ulcers

RESPOND Restoring Equilibrium and Wound Stimulation to Promote Healing Of Non-healing DFUs

Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management

Study of Miro3D Wound Matrix for Healing Wounds and Ulcers in Outpatient Care

Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Open Wounds

PREPUP: A Randomized Trial of Bonvadis® Versus Collagenase Ointment in Diabetic Foot Ulcers

A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers

Characterization of AmnioExcel Plus in Two Treatment Paradigms

NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers

Prospective, Multicenter, RCT of the Tenex Ultrasound System

Nonhealing Venous Leg Ulcers Treated With a Standard of Care (SoC) Alone or Standard of Care and Dehydrated Human Placenta Tissue (dHPT) With Crossover